Payment overview · 2025
General Payments
$191.95
11 reported records · 11 companies
Healthcare provider profile · identity verified
John A Gabis, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHILLICOTHE, OH · NPI 1528072311
Verified facts
What the public records show
CMS Open Payments records show John A Gabis, MD received $191.95 in general payments during 2025 across 11 reported records.
Astellas Pharma US Inc accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.16 | 15.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.37 | 11.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.08 | 8.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.90 | 8.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.89 | 8.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.75 | 8.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.60 | 8.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.59 | 8.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.56 | 8.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.06 | 7.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.99 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.95 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 259 | 70 |
| Lisinopril | Lisinopril | 162 | 47 |
| Omeprazole | Omeprazole | 101 | 25 |
| Eliquis | Apixaban | 94 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 66 | 20 |
| Gabapentin | Gabapentin | 65 | 18 |
| Atenolol | Atenolol | 59 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | 16 |
| Losartan Potassium | Losartan Potassium | 52 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 12 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 11 |
| Metformin Hcl | Metformin Hcl | 38 | 13 |
| Furosemide | Furosemide | 36 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.95 · 11 records | Astellas Pharma US Inc | AIRSUPRA, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, REXULTI, VOQUEZNA, VRAYLAR, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error